Enanta Pharmaceuticals (ENTA) Return on Capital Employed (2013 - 2026)
Enanta Pharmaceuticals (ENTA) reported Return on Capital Employed of 21.91% for Q1 2026, up 1332.0% on a YoY basis from 1.53% in Q1 2025, and up 21.93% quarter-over-quarter from 28.06% in Q4 2025.
Enanta Pharmaceuticals (ENTA) Return on Capital Employed (2013 - 2026) Analysis & Trends
Enanta Pharmaceuticals has reported Return on Capital Employed for 14 years, with the latest figure at 21.91% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 1332.0% year-over-year to 21.91%; the trailing twelve-month figure through Mar 2026 stood at 21.91% (up 1332.0% YoY), and the FY2025 full-year result was 30.47%, up 316.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 21.91%, up from 28.06% in the prior quarter.
- The five-year high for Return on Capital Employed was 21.91% in Q1 2026, with the low at 42.34% in Q1 2023.
- Historically, Return on Capital Employed has averaged 34.86% across 5 years, with a median of 35.31% in 2024.
- Annual changes were most pronounced in 2022 — Return on Capital Employed slumped 1465 bps — and 2026, when it soared 1332 bps.
- Enanta Pharmaceuticals' Return on Capital Employed stood at 36.47% in 2022, then declined by 2 bps to 37.1% in 2023, then gained by 5 bps to 35.19% in 2024, then advanced by 20 bps to 28.06% in 2025, then advanced by 22 bps to 21.91% in 2026.
- The last three Return on Capital Employed figures came in at 21.91% (Q1 2026), 28.06% (Q4 2025), and 35.22% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Enanta Pharmaceuticals | 365.48 Mn | 201.71 Mn | - | -21.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.91% |
| Dec 31, 2025 | -28.06% |
| Sep 30, 2025 | -35.22% |
| Jun 30, 2025 | -36.20% |
| Mar 31, 2025 | -35.23% |
| Dec 31, 2024 | -35.19% |
| Sep 30, 2024 | -36.85% |
| Jun 30, 2024 | -35.31% |
| Mar 31, 2024 | -36.95% |
| Dec 31, 2023 | -37.10% |
| Sep 30, 2023 | -32.99% |
| Jun 30, 2023 | -38.88% |
| Mar 31, 2023 | -42.34% |
| Dec 31, 2022 | -36.47% |
| Sep 30, 2022 | -35.34% |
| Jun 30, 2022 | -34.99% |
| Mar 31, 2022 | -33.55% |
| Dec 31, 2021 | -31.78% |
| Sep 30, 2021 | -26.83% |
| Jun 30, 2021 | -22.21% |